Matches in SemOpenAlex for { <https://semopenalex.org/work/W3090162015> ?p ?o ?g. }
Showing items 1 to 71 of
71
with 100 items per page.
- W3090162015 abstract "Since 1982, oral isotretinoin has been indicated for the treatment of severe nodular-cystic acne, but indications for its use have expanded significantly in recent decades. Dermatologists around the world have begun to actively use isotretinoin for moderate and even mild forms of acne, for acne that is resistant to standard treatment methods, as well as if the patient has a tendency to scar formation, which indirectly confirms that most often the benefits obtained from the use of the drug are significantly higher than the possible risk of side effects. Despite 38 years of experience with isotretinoin, currently some dermatologists unreasonably avoid prescribing the drug. Analysis of the literature and our own experience show that this attitude to acne therapy with systemic isotretinoin is usually associated with insufficient or inadequate awareness of doctors and patients. The most common reason why systemic isotretinoin therapy is not prescribed is fear of the risk of side effects during treatment.Therefore, the aim of the work was to determine the profile and frequency of side effects in acne treatment with systemic isotretinoin. For this purpose, we retrospectively analyzed 76 outpatient records of patients receiving systemic isotretinoin in the complex therapy of acne. Among the patients there were 51 women aged 13 to 42 years and 25 men aged 14 to 39 years. Roaccutane (F. Hoffmann-La Roche Ltd, Switzerland) was used as a systemic therapy for acne. The regimen of therapy with Roaccutane was as follows: for the first 2 months — 0.3—0.4 mg per 1 kg of body weight per day, then with normal biochemical parameters of liver, kidney function, lipid and carbohydrate metabolism, the daily dose increased to 0.5—0.7 mg per 1 kg of the patient’s body weight until a cumulative dose of 120 mg per kg of body weight is reached. In all patients who received Roaccutane for the treatment of acne, side effects were well tolerated, easily corrected and sometimes required only a temporary reduction in its daily dose. Changes in the biochemical blood test were transient: the indicators were restored to normal values after the end of the course of therapy." @default.
- W3090162015 created "2020-10-08" @default.
- W3090162015 creator A5067721038 @default.
- W3090162015 date "2020-09-18" @default.
- W3090162015 modified "2023-09-25" @default.
- W3090162015 title "Adverse effects of systemic retinoids in treatment of acne: what are doctor and patient afraid of?" @default.
- W3090162015 cites W162196013 @default.
- W3090162015 cites W1969067090 @default.
- W3090162015 cites W1969381453 @default.
- W3090162015 cites W2007007770 @default.
- W3090162015 cites W2116713827 @default.
- W3090162015 cites W2119027047 @default.
- W3090162015 cites W2147797128 @default.
- W3090162015 cites W2150788930 @default.
- W3090162015 cites W2177747184 @default.
- W3090162015 cites W2185309897 @default.
- W3090162015 cites W2276726626 @default.
- W3090162015 cites W2356681623 @default.
- W3090162015 cites W2558758615 @default.
- W3090162015 cites W2916018902 @default.
- W3090162015 cites W95894692 @default.
- W3090162015 doi "https://doi.org/10.30978/ujdvk2020-3-50" @default.
- W3090162015 hasPublicationYear "2020" @default.
- W3090162015 type Work @default.
- W3090162015 sameAs 3090162015 @default.
- W3090162015 citedByCount "0" @default.
- W3090162015 crossrefType "journal-article" @default.
- W3090162015 hasAuthorship W3090162015A5067721038 @default.
- W3090162015 hasConcept C121608353 @default.
- W3090162015 hasConcept C126322002 @default.
- W3090162015 hasConcept C16005928 @default.
- W3090162015 hasConcept C185926286 @default.
- W3090162015 hasConcept C197934379 @default.
- W3090162015 hasConcept C2776285725 @default.
- W3090162015 hasConcept C2777673923 @default.
- W3090162015 hasConcept C2780035454 @default.
- W3090162015 hasConcept C2780542314 @default.
- W3090162015 hasConcept C2781413609 @default.
- W3090162015 hasConcept C530470458 @default.
- W3090162015 hasConcept C71924100 @default.
- W3090162015 hasConcept C98274493 @default.
- W3090162015 hasConceptScore W3090162015C121608353 @default.
- W3090162015 hasConceptScore W3090162015C126322002 @default.
- W3090162015 hasConceptScore W3090162015C16005928 @default.
- W3090162015 hasConceptScore W3090162015C185926286 @default.
- W3090162015 hasConceptScore W3090162015C197934379 @default.
- W3090162015 hasConceptScore W3090162015C2776285725 @default.
- W3090162015 hasConceptScore W3090162015C2777673923 @default.
- W3090162015 hasConceptScore W3090162015C2780035454 @default.
- W3090162015 hasConceptScore W3090162015C2780542314 @default.
- W3090162015 hasConceptScore W3090162015C2781413609 @default.
- W3090162015 hasConceptScore W3090162015C530470458 @default.
- W3090162015 hasConceptScore W3090162015C71924100 @default.
- W3090162015 hasConceptScore W3090162015C98274493 @default.
- W3090162015 hasLocation W30901620151 @default.
- W3090162015 hasOpenAccess W3090162015 @default.
- W3090162015 hasPrimaryLocation W30901620151 @default.
- W3090162015 hasRelatedWork W10356435 @default.
- W3090162015 hasRelatedWork W11803770 @default.
- W3090162015 hasRelatedWork W12336777 @default.
- W3090162015 hasRelatedWork W13682529 @default.
- W3090162015 hasRelatedWork W19667489 @default.
- W3090162015 hasRelatedWork W19945932 @default.
- W3090162015 hasRelatedWork W20222192 @default.
- W3090162015 hasRelatedWork W310038 @default.
- W3090162015 hasRelatedWork W6770659 @default.
- W3090162015 hasRelatedWork W9575031 @default.
- W3090162015 isParatext "false" @default.
- W3090162015 isRetracted "false" @default.
- W3090162015 magId "3090162015" @default.
- W3090162015 workType "article" @default.